Health Care

Senator Feinstein strongly supports universal health care for all Americans, and with her colleagues in the Senate, stopped Republicans attempt to repeal the Affordable Care Act.

Universal Health Care

In 2009, when the Senate was considering the Affordable Care Act, she sponsored legislation to create a public option to compete with private health insurance. In the current Senate session, she has sponsored legislation to create a public option based on Medicare available to all Americans.

Senator Feinstein also supports:

  • Lowering the age for Medicare eligibility to 55
  • Mandating that Medicare negotiates for drug prices (which it currently does not)
  • Allowing the US Department of Health and Human Services to reject unreasonable premium increases
  • And requiring 85 percent of all premium dollars to go to patients, instead of 80 percent.



The National Committee to Preserve Social Security and Medicare endorsed Senator Feinstein’s reelection, citing her efforts to “ensure the solvency of the Social Security and the Medicare Hospital Insurance trust funds, to provide adequate funding to the Social Security Administration, to establish a meaningful Medicare prescription drug program, and for her unflagging opposition to Social Security and Medicare privatization schemes are a matter of record.”

Protecting Reproductive Rights

Senator Feinstein has committed to protecting a woman’s right to choose and has earned a 100 percent rating from Planned Parenthood for standing up for women’s reproductive health choices. Planned Parenthood Action Fund and NARAL Pro-Choice America have endorsed her reelection.

Supporting Medical Research

As co-chair of the Senate Cancer Coalition, Senator Feinstein has also been a leader in increasing funding for disease research. She helped stop Donald Trump's plan to cut funding from the National Institutes of Health and introduced bipartisan legislation to improve breast cancer detection.

She also sponsored the Lung Cancer Mortality Reduction Act, which led to an improved emphasis and strategy for research of top deadly cancers.